Connect with us

Cannabis News

As Massachusetts Marijuana Legalization Rollback Nears Ballot, New State Report Shows Regulated Market Reaching Most Consumers

Published

2 months ago

on

As Massachusetts voters face a November ballot initiative to roll back the state’s recreational marijuana law, a new report from officials finds legalization is achieving one of its main goals: stopping the illegal sale of cannabis as adults move into the regulated market.

A Cannabis Control Commission (CCC) report released Friday found that among adults who used marijuana in the past year, 84 percent said they got their cannabis from a licensed source.

“Adult consumers are moving away from mostly unregulated sources as the state’s adult marijuana industry enters its eighth year of operation,” says a CCC press release about the report.

with that More than $9 billion in gross sales since the launch of the adult-use market in 2018this data point indicates that illegal sales are becoming very successful; Advocates worked to drive home the impact of the policy while building support for legalization.

The analysis — which also looked at usage trends, self-reported health benefits, public opinion on legalization and more — interviewed 11,635 Massachusetts residents ages 16-65. (State law prohibits the sale of recreational cannabis to those under 21, but the CCC included younger people in the survey to understand trends in that cohort, t0o.)

“This new research shows that Massachusetts residents are moving away from the illegal market when safe and well-regulated options are available,” CCC Executive Director Travis Ahern said in a press release. “We will continue to monitor sources like the (International Cannabis Policy Study or ICPS) to guide our mission to oversee an efficient and fair cannabis market in Massachusetts.”

Here are some other findings from the report:

  • Nearly half of cannabis users (43%) said they used it to “manage or improve mental health.”
  • The frequency of cannabis use “generally increased year-on-year across all 16-20 age groups, where it decreased from 2019 to 2023.”
  • People are more likely to report using marijuana flower products (70 percent) than other product categories.
  • Overall, 81 percent said they supported legalizing adult use based on the 2023 survey data, which was “a slight decline from 83 percent support in the 2022 wave.”

“New analysis of ICPS data provides valuable insight into patterns of use and levels of education around cannabis use,” said CCC Research Lead Julie Johnson. he said.

“We are also making recommendations to help strengthen future data analysis and collection, including future research collaborations with other regulators and public health professionals and the initiation of larger studies to guide cannabis-related impairment and assess health care utilization,” he said. “We also encourage more resources to be directed to public awareness and youth education, with ample funding available through tax revenue generated from the sale of cannabis.”

The fact that 81 percent of Massachusetts residents said they supported legalization in a recent poll raises questions about the chances of anti-cannabis initiatives getting the majority needed to pass the November ballot.

A separate survey published earlier this month Residents were specifically asked about their position on the measure of withdrawal It found that 63% were against it, including 48% who said they were “strongly” against it. Only 20 percent of respondents said they supported the proposed initiative, while 11 percent “strongly” supported repeal.

The survey comes a month after cannabis activists filed a complaint with the State Voting Law Commission under the Secretary of State, alleging that petitioners with anti-cannabis campaigns used deceptive tactics to convince voters to allow them to cast their ballots.

The commission withdrew the complaint in January, however, and the ballot measure was challenged, advocates said raised “unsupported allegations” about the adequacy of the signature collection process they said he needed an official exam.

The decision marked a setback for advocates and industry players who have reported numerous accounts of alleged misconduct by applicants working on behalf of the Coalition for a Healthy Massachusetts.

He came anyway A separate survey found that nearly half of those who signed a petition to repeal marijuana sales felt cheatedaccording to many, the measure was presented to them as a proposal to deal with unrelated issues such as public education and expanded housing.

The anti-marijuana coalition has denied any wrongdoing in the signature collection process and dismissed the poll results.

The initiative would still allow adults 21 and older to possess and give away an ounce of cannabis, but it would repeal provisions of the voter-approved legalization law that allow commercial sales and home cultivation by adults. The medical cannabis program would remain intact under that measure.

A state association of marijuana companies urged voters to report them to local officials if they observe them Instances of “spoof mail” or other fraudulent solicitation tactics.

The office of Massachusetts Attorney General Andrea Campbell (D), that is He cleared the signature collection campaign in September—stressed the importance of voters reading the summary at the top of the signature form before signing any petition.

The Massachusetts legislature took up the initiative earlier this month when the 2026 session began. Since the state electoral commission has issued a resolution on the complaint, the members of parliament have until May 5 to act on the proposal. If they decide not to pass it in the legislature, the campaign would have to go through another round of petitions and get at least 12,429 certified signatures by July 1 to get on the November ballot.

Meanwhile, the head of Massachusetts’ marijuana regulatory agency recently suggested measures to effectively recriminalize the sale of recreational cannabis. dangerous tax revenues being used to support substance abuse treatment efforts and other public programs.

Massachusetts lawmakers recently joined a bicameral conference committee to hammer out a deal. double the legal limit for possession of marijuana for adults and review the regulatory framework for the state’s adult cannabis market.

In December, state regulators, too established rules for social marijuana consumption halls.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

CCC has recently launched a targeted online platform helping people find work, on-the-job training and networking opportunities in the state’s legal cannabis industry.

State legislators have also been pondering imposing stricter restrictions on intoxicating hemp-derived products and a plan allowing individual entities to control a greater number of cannabis establishments.

Also in Massachusetts Legislators working on state budgets butted heads with CCC officialswho said critical technology improvements can’t be made without more money from the legislature.

Massachusetts lawmakers also passed a bill establishing a pilot program for the regulated therapeutic use of psychedelics. And they have two committees Hearings to discuss additional measures related to psilocybin were held separately.

user photo Brian Shamblen.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Cannabis operators report mixed results as rescheduling reshapes the financial outlook

Published

7 hours ago

on

May 14, 2026

By

The rescheduling came mid-quarter and rewrote the tax math for each medical sales operator, but the underlying revenue picture remained uneven in early 2026, with acquisitions driven at one end of the scale and continued top-line compression at the other.

Vireo Growth: Back on $106 million deal
Vireo Growth Inc. reported Q1 GAAP revenue of $106.2 million, up 333.5% year-over-year, driven almost entirely by recent acquisitions rather than organic growth. The company completed the Schwazze acquisition in March, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico. At the end of the quarter, it closed Eaze and Hawthorne Gardening, FLUENT Corp. announced an acquisition agreement and executed a California dispensary joint venture with Glass House Brands. Treating all acquisitions as closed on January 1, 2025 on a pro forma basis, revenue was $210.2 million and adjusted EBITDA was $42.2 million. The company ended the quarter with $137.8 million in cash.

John Mazarakis, CEO of Vireo, said: “Performance in the first quarter met our expectations and we are excited to welcome Schwazze, Eaze and Hawthorne to Vireo. We are focused on integration and optimization across the platform, while remaining opportunistic regarding growth opportunities associated with further acquisitions.”

Cresco Labs: $151 million, 280E relief and Texas license
Cresco Labs reported Q1 revenue of $151 million, down from $165.8 million in Q1 2025. Adjusted gross margin was 50.7% and adjusted EBITDA margin of $33 million was 21.7%. Cash at the end of the quarter was $67 million against a $310 million secured term loan. The company was conditionally granted a Texas Compassionate Use Program license after the quarter ended and opened two new dispensaries in Ohio.

Management said, “Moving the state’s legal medical cannabis from Schedule I to Schedule III is the most impactful reform this industry has seen, and it validates the work we’ve been executing for years. We’ve built the operational foundation and balance sheet discipline to reap the immediate benefits of rescheduling, and position Cresco to take advantage of the broader path to normalization.”

Jushi Holdings: 4% growth, 460 basis point margin expansion
Jushi Holdings reported first-quarter revenue of $66.4 million, up 4% year-over-year, with gross profit margin up 460 basis points to 45%. Adjusted EBITDA was $11.4 million, up 17.2%. The margin improvement was driven by higher production volumes in Ohio, Massachusetts and Pennsylvania and the performance of grower processors. Jushi brand products accounted for 58% of retail revenue in vertical markets. The company refinanced $132.3 million in debt during the quarter, providing $160 million in new debt through 2029.

Jim Cacioppo, president and CEO, said: “The recent scheduling of state-licensed medical marijuana for Schedule III is an important milestone for the industry, eliminating 280E tax limitations for medical operations and supporting a more favorable long-term operating environment.” Medical sales accounted for about 60% of Jushi’s 2025 revenue, making this material relief.

iAnthus Capital: Revenue falls to $33.5 million
iAnthus Capital reported first-quarter revenue of $33.5 million, down $4.6 million from 2025’s first quarter. Gross margin was 47.5%, up 477 basis points from the 2025 quarter. The company did not provide a management comment in the press release.

Country farms: international export record, fourth consecutive quarter of net income
Village Farms International reported first quarter consolidated net sales of $50.2 million, up 27% year-over-year, with net income of $2.9 million and adjusted EBITDA of $9.9 million, up 118% year-over-year. International export sales increased 171% to a record $14.6 million, driven by demand for EU-GMP compliant products in Germany. Pure Sunfarms had the top Canadian market share in dried flowers for the 15th consecutive month. The company started planting the first half of its Delta 2 greenhouse expansion and expects its Phase II facility in the Netherlands to reach full capacity by the end of 2026, which would quadruple Dutch production.

Michael DeGiglio, President and CEO, said: “Our first quarter results reflect a strong start to the year and continued momentum in our largest markets, with adjusted EBITDA growth of 118% year-over-year, significantly outpacing revenue growth of 27%, driven by our international business and continued leadership in Canada.

Cronos Group: Record revenue, $822 million in cash
Cronos Group reported Q1 net income of $45.2 million, up 40% year-over-year and a record quarter, with net income of $15.7 million and adjusted EBITDA of $5.1 million. Israel led growth PEACE NATURALS grew 53% for ninth consecutive record quarter. In Canada, the Spinach brand took first place in vapes with a 9.8% share of the national market, and maintained its top spot in edibles at 20.8%. The company ended the quarter with $821.9 million in cash and authorized a new $50 million stock repurchase program. The deadline to close the acquisition of CanAdelaar, one of the ten licensed growers in the Dutch Controlled Cannabis Supply Chain Experiment, has been extended to September 9, 2026 to allow time for regulatory approvals.

Mike Gorenstein, chairman, president and CEO, said, “Cronos achieved net earnings and gross profit in the first quarter as we continue to execute against our unlimited product strategy and the additional supply from Cronos GrowCo’s expansion fuels the next phase of our growth.”

Org chart: Revenue down 9%, Sanity Group acquisition closes after quarter
Organigram Global reported fiscal second quarter net income of $59.8 million, down 9% year-over-year, with adjusted EBITDA of $0.9 million, down 82%. Lower vape and pre-infusion sales drove the decline, along with a $5.8 billion dent in the U.S. hemp business. The company achieved a record quarterly harvest of over 32,000kg at its Moncton facility, up 56% year-on-year, and launched 10 SKUs in Australia targeting over 4,000 pharmacies. At the end of the quarter, Organigram acquired Sanity Group, one of Germany’s leading cannabis companies, and updated its 2026 guidance to net revenue of more than $350 million.

James Yamanaka, CEO, said: “Q2 reflected our poor performance in vaporizers and temporary challenges in pre-infusion production, compounded by slower industry growth. We have acted quickly to address these issues, and the operational changes and product improvements we have implemented are already beginning to stabilize performance.”

Greg Guyatt, Chief Financial Officer, said: “The financial impact of the competitive and operational challenges encountered earlier in fiscal 2026 is believed to have materialized in the first half of the year, and we are now beginning to stabilize performance. We expect to resume a trajectory of margin expansion and improved profitability during the second half of the year, supported by positive revenue and international sales growth. The Sanity Group.”

Continue Reading

Cannabis News

Medical Marijuana Helps Pain Patients Reduce Use Of Opioids, New Study Shows

Published

7 hours ago

on

May 14, 2026

By

As opioids continue to cause overdose deaths, a new study suggests that making medical cannabis available and affordable could help patients reduce their use of prescription painkillers.

“Although cannabis has historically been characterized as a potential ‘gateway drug,’ it may also serve as a harm reduction tool for some patients seeking to reduce their reliance on higher-risk opioid medications,” researchers at the University of Pennsylvania Perelman School of Medicine found.

The study, a prospective observational trial at the Hospital of the University of Pennsylvania, followed 29 adults over five months. All had been living with chronic pain for years—an average of 11 years—and were already taking opioid medications, but struggled to taper off of them despite other treatments.

The study is unique in its focus on cost as a factor in access to medical marijuana, with the researchers describing their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.”

Participants were recruited from a university outpatient chronic pain clinic and then completed monthly pain assessments using the Numeric Pain Rating Scale (NRS). The researchers measured daily opioid use, measured in milligrams of morphine equivalents (MME).

“Seven patients (24%) were able to completely discontinue opioid therapy at the end of the study, five of whom did so by the second month. Pain levels also decreased over time,” the authors wrote.

Notably, “there was a statistically significant reduction in mean pain scores experienced over the five-month study period,” says the paper published in the Cureus Journal of Medical Science.

“There was also a reduction in average opioid consumption of about 32 MME per day, which remained the same throughout the follow-up. In addition, seven patients were able to completely discontinue opioid therapy during the study.”

“Mean daily opioid consumption decreased from 46.8 MME/day at baseline to 16.2 MME/day at one month and remained low during the five-month follow-up period,” the researchers found.

What set the new study apart was not just the inclusion of medical cannabis, but the deliberate removal of cost as a barrier. Participants “consistently identified cost as a major barrier to initiating medical cannabis” before enrolling in the study, the document says.

Noting the novelty of the study, they added their hypothesis: “Improving access to medical cannabis will allow a subset of patients, especially those with a high cost barrier, to reduce or discontinue opioid use while maintaining adequate pain control.”

“These results suggest that medical cannabis may be a useful adjunctive therapy to reduce opioid use, relieve chronic pain, and improve health-related quality of life,” they concluded.

“The findings of this study add to the body of literature supporting the safety profile and potential therapeutic role of cannabis.”

The studies the authors are cautious in their conclusions, warning of limitations and the need for further research. “The sample size was small and derived from a single clinical site, and there was no control group.” And because “patients self-titrate cannabis products, leading to variability in dosage and frequency of use,” the findings are not standardized.

But the authors concluded that “when used under appropriate medical supervision, medical cannabis may be an effective adjunctive strategy to reduce opioid use among patients receiving long-term opioid therapy.”

This study follows a Recent research shows that using medical marijuana helps people reduce their use of other drugs, including opioids.sleep aids and antidepressants. They also experience fewer negative side effects after switching from prescription drugs to cannabis, according to a study involving more than 3,500 patients.

It also comes from behind President Donald Trump says marijuana ‘can make people feel a lot better’ and serves as a “substitute for addictive and potentially lethal opioids.”

Last month, the Trump administration announced it moving forward with federal reclassification of marijuana medicinal cannabis is classified under Schedule I to III of the Controlled Substances Act.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Livermore Falls debates cannabis licensing fees

Published

1 day ago

on

May 13, 2026

By











Existing medical cannabis licensing fees will be temporarily applied to recreational marijuana businesses, the Select Committee decided on May 5. Board members agreed 4-1 to the temporary change, as long as officials say the fees are higher than necessary and accurately reflect the town’s oversight costs.

Bryce Cobb, Livermore Falls’ code enforcement officer, plumbing inspector, health officer and E-911 dispatcher, said voters approved the amended cannabis ordinance on April 28. Cobb said the amended ordinance allows recreational marijuana businesses and the next step was to establish a fee schedule. Recreational cannabis businesses operating in town would require local licensing approval under the ordinance.

Asked if he had fee schedules from other towns to compare, Cobb said he did not. Additionally, the town’s fee schedule specifically mentions medicinal cannabis.

“So it could be medical and adult use,” Cobb said when discussing whether the existing fee structure could apply to recreational businesses.

Read more at Sun Magazine










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media